These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 30725444)

  • 41. Emergence of Novel Human Norovirus GII.17 Strains Correlates With Changes in Blockade Antibody Epitopes.
    Lindesmith LC; Kocher JF; Donaldson EF; Debbink K; Mallory ML; Swann EW; Brewer-Jensen PD; Baric RS
    J Infect Dis; 2017 Dec; 216(10):1227-1234. PubMed ID: 28973354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Self-assembly of the recombinant capsid protein of a swine norovirus into virus-like particles and evaluation of monoclonal antibodies cross-reactive with a human strain from genogroup II.
    Almanza H; Cubillos C; Angulo I; Mateos F; Castón JR; van der Poel WH; Vinje J; Bárcena J; Mena I
    J Clin Microbiol; 2008 Dec; 46(12):3971-9. PubMed ID: 18842943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genogroup IV and VI canine noroviruses interact with histo-blood group antigens.
    Caddy S; Breiman A; le Pendu J; Goodfellow I
    J Virol; 2014 Sep; 88(18):10377-91. PubMed ID: 25008923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural Basis of Nanobodies Targeting the Prototype Norovirus.
    Ruoff K; Kilic T; Devant J; Koromyslova A; Ringel A; Hempelmann A; Geiss C; Graf J; Haas M; Roggenbach I; Hansman G
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30602609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Norovirus GII.4 antibodies in breast milk and serum samples: their role preventing virus-like particles binding to their receptors.
    Khodayar-Pardo P; Martínez-Costa C; Carmona-Vicente N; Buesa J
    Pediatr Infect Dis J; 2014 Jun; 33(6):554-9. PubMed ID: 24830517
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunological Cross-Reactivity of an Ancestral and the Most Recent Pandemic Norovirus GII.4 Variant.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Viruses; 2019 Jan; 11(2):. PubMed ID: 30678195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a broad-spectrum therapeutic Fc-nanobody for human noroviruses.
    Hansman GS; Kher G; Svirina AD; Tame JRH; Hartley-Tassell L; Irie H; Haselhorst T; von Itzstein M; Rudd PA; Pancera M
    J Virol; 2024 Jul; 98(7):e0070724. PubMed ID: 38953655
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression and purification of norovirus virus like particles in Escherichia coli and their immunogenicity in mice.
    Huo Y; Wan X; Ling T; Wu J; Wang W; Shen S
    Mol Immunol; 2018 Jan; 93():278-284. PubMed ID: 28802994
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of a norovirus GII-specific antigenic epitope.
    Liu J; Wang Z; Ma J; Ji S; Huo Y
    Arch Virol; 2024 May; 169(6):131. PubMed ID: 38819530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002.
    Lindesmith LC; Debbink K; Swanstrom J; Vinjé J; Costantini V; Baric RS; Donaldson EF
    J Virol; 2012 Jan; 86(2):873-83. PubMed ID: 22090098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-Resolution Mapping of Human Norovirus Antigens via Genomic Phage Display Library Selections and Deep Sequencing.
    Huang W; Soeung V; Boragine DM; Hu L; Prasad BVV; Estes MK; Atmar RL; Palzkill T
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33055250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.
    Debbink K; Lindesmith LC; Donaldson EF; Swanstrom J; Baric RS
    J Virol; 2014 Jul; 88(13):7256-66. PubMed ID: 24741081
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanisms of GII.4 norovirus persistence in human populations.
    Lindesmith LC; Donaldson EF; Lobue AD; Cannon JL; Zheng DP; Vinje J; Baric RS
    PLoS Med; 2008 Feb; 5(2):e31. PubMed ID: 18271619
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Viral Immunol; 2016 Jun; 29(5):315-9. PubMed ID: 27135874
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of Functional Norovirus Antibody Responses by Blocking Assay in Mice.
    Malm M; Tamminen K; Blazevic V
    Methods Mol Biol; 2016; 1403():259-68. PubMed ID: 27076135
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural analysis of determinants of histo-blood group antigen binding specificity in genogroup I noroviruses.
    Shanker S; Czako R; Sankaran B; Atmar RL; Estes MK; Prasad BV
    J Virol; 2014 Jun; 88(11):6168-80. PubMed ID: 24648450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pandemic GII.4 Sydney and Epidemic GII.17 Kawasaki308 Noroviruses Display Distinct Specificities for Histo-Blood Group Antigens Leading to Different Transmission Vector Dynamics in Pacific Oysters.
    Morozov V; Hanisch FG; Wegner KM; Schroten H
    Front Microbiol; 2018; 9():2826. PubMed ID: 30542329
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional and structural characterization of Norovirus GII.6 in recognizing histo-blood group antigens.
    Cong X; Li HB; Sun XM; Qi JX; Zhang Q; Duan ZJ; Xu Y; Liu WL
    Virol Sin; 2023 Feb; 38(1):56-65. PubMed ID: 36216242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human norovirus inhibition by a human milk oligosaccharide.
    Koromyslova A; Tripathi S; Morozov V; Schroten H; Hansman GS
    Virology; 2017 Aug; 508():81-89. PubMed ID: 28505592
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mapping broadly reactive norovirus genogroup I and II monoclonal antibodies.
    Crawford SE; Ajami N; Parker TD; Kitamoto N; Natori K; Takeda N; Tanaka T; Kou B; Atmar RL; Estes MK
    Clin Vaccine Immunol; 2015 Feb; 22(2):168-77. PubMed ID: 25428246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.